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Besides its cardiotoxic effect, doxorubicin also elicits inflammatory effects in vivo. 7-Monohydroxyethylrutoside (monoHER) has
recently been used as a protector against doxorubicin-induced cardiotoxicity in vivo. It is not known yet whether monoHER can also
protect against doxorubicin-induced inflammatory effects. The aim of the present study was (1) to illustrate the inflammatory effects
of doxorubicin in vitro and (2) to evaluate a possibly protective effect of monoHER. In order to demonstrate the inflammatory effects
of doxorubicin and the possible protection of monoHER, proliferating human umbilical cord vascular endothelial cells (HUVECs)
were incubated with different concentrations of doxorubicin ranging from 12.5 to 600nM with(out) 200mM monoHER. Resting
(confluent) HUVECs were incubated with (0.5–25mM) doxorubicin with(out) monoHER (0.2–1.2mM) and the viability of
endothelial cells and their propensity to adhere to neutrophils were measured 24h after treatment. The localisation of adhered
neutrophils was determined with immunofluorescence microscopy. To further characterise the mechanism of doxorubicin-induced
neutrophil adhesion, the expression of the HUVECs surface adhesion molecules was determined after doxorubicin treatment.
Doxorubicin decreased the viability and proliferation capacity of HUVECs in a concentration-dependent manner. The proliferating
HUVECs were much more sensitive to doxorubicin (IC50¼60.0720.8nM) than resting cells (LC50¼4.070.3mM). Doxorubicin also
increased the adhesion of neutrophils reaching a plateau value at a doxorubicin concentration of X0.4mM (P¼0.0113). The induced
neutrophil adhesion was accompanied by overexpression of VCAM and E-selectin but not ICAM. Although monoHER did not
reverse the effect of doxorubicin on the proliferation of endothelial cells, it significantly protected resting HUVECs against the
cytotoxic effect of doxorubicin (p25mM, Po0.0015). In addition, monoHER completely protected against the stimulatory effect of
doxorubicin on neutrophil adhesion, and inhibited the doxorubin-induced expression of VCAM and E-selectin on the surface of
treated HUVECs. This study illustrates that monoHER, which protects against doxorubicin’s cardiotoxic effect, can also protect
against doxorubicin-induced inflammatory effects. These data prompt further investigation about the possible link between
doxorubicin-induced inflammatory effects and its cardiotoxicity in vivo.
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Doxorubicin is a well-known chemotherapeutic agent used against
a wide range of human malignancies. The development of acute
and chronic cardiotoxicity (Schwartz et al, 1993), however, limits
the clinical use of doxorubicin. The mechanism of doxorubicin-
induced cardiotoxicity is still not fully understood. The prevailing
hypothesis, however, suggests that the cardiotoxicity results from
the formation of reactive oxygen species (ROS) (e.g. hydroxyl
(OH.) and superoxide anion (O
 .
2 ) radicals) (Olson and Mushlin,
1990; Takacs et al, 1992; Goeptar et al, 1994). Reactive oxygen
species affect heart tissue specifically because of its relatively low
antioxidants content (e.g. SOD and catalase) and the relative
abundance of mitochondria (Takacs et al, 1992).
In addition to its cardiotoxic effects, doxorubicin elicits also
inflammatory effects as illustrated by the occurrence of phlebitis
(Hecker, 1990) and acute inflammatory reactions in the eyelid of
different laboratory animals (McLoon and Wirtschafter, 1997).
Doxorubicin also causes inflammatory reactions in the vicinity of
heart tissue where it was found to increase the incidence of
thrombus formation in the atrium of mice (Fujihira et al, 1993).
Recently, we have shown that 7-monohydroxyethylrutoside
(monoHER) could protect against doxorubicin-induced cardio-
toxicity in the mouse (Van Acker et al, 2000; Van Acker et al,
1997). MonoHER cardioprotection is believed to result from the
protection against doxorubicin-induced free radicals as a good
antioxidant and metal ion chelating agent (Haenen et al, 1993; Van
Acker et al, 1993). Since the mechanism of monoHER is not fully
established, it is also important to study the effect of monoHER on
the inflammatory effects of doxorubicin.
Accordingly, the aim of this study was to establish a model
showing the inflammatory effects of doxorubicin in vitro. Using
this model, the effect of doxorubicin on the viability and
proliferating capacity of human vascular endothelial Cells
(HUVECs) was studied. Furthermore, the effect of doxorubicin Revised 7 April 2003; accepted 13 April 2003
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son the neutrophil adhesion of HUVECs was studied. In the mean
time, the expression of several adhesion molecules on the surface
of doxorubicin-treated HUVECs was also studied. The study was
completed by investigating the protection obtained by monoHER
against the inflammatory effects of doxorubicin in that model.
MATERIALS AND METHODS
Chemicals
7-monohydroxyethylrutoside was kindly provided by Novartis
Consumer Health (Nyon, Switzerland). Doxorubicin HCl was
purchased from Pharmacia Upjohn BV (Woerden, The Nether-
lands). Potassium chloride, sodium chloride, ammonium chloride,
EDTA (disodium salt), potassium bicarbonate and dimethyl
sulphoxide (DMSO) were purchased from Merck (Amsterdam,
The Netherlands), bovine serum albumin, trypsin, 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and
phenyl methyl sulphonyl chloride (PMSF) from Sigma-Aldrich
Chemie (Zwijndrecht, The Netherlands), D-glucose and nonidet
P40 (NP40) from Fluka Biochemika (Buchs, Switzerland), human
serum from CLB (Amsterdam, The Netherlands) and M199, fetal
calf serum (FCS) and HBSS (without calcium) from Life
Technologies (Breda, The Netherlands). Calcein AM was from
Molecular Probes Europe BV (Leiden, The Netherlands), Ficoll
from Pharmacia Biotech AB (Upssala, Sweden) and tumour
necrosis factor a (TNFa), L-glutamine, fibronectin (human
plasma), heparin and HEPES from ICN Biomedicals (Aurora,
OH). Endothelial cell growth factor (ECGF) was extracted from
bovine hypothalamus as previously mentioned (Maciag et al,
1979).
Human vascular endothelial cells isolation and culture
Human vascular endothelial cells were isolated as previously
described (Verheul et al, 2000). In brief, the umbilical cord vein
was filled with trypsin/EDTA, after being washed with warm PBS,
and incubated at 371C for 20min. The dissociated cells were
collected by washing the vein with PBS and the cell suspension was
centrifuged at 241g for 7min. The cell pellet was quickly
resuspended in culture medium (M199 containing 10% human
serum, 10% FCS, 5Uml
 1 heparin, 200IEml
 1 penicillin and
200mg streptomycin, 0.29 mgml
 1 L-glutamine and 50mgml
 1
ECGF). Endothelial cells passage 2 (P2), plated in fibronectin-
precoated 96-well flat-bottom microtitre plate (Costar, Badhoeve-
dorp, The Netherlands), was used during the whole study.
Proliferation assay (IC50)
Human vascular endothelial cells were plated on precoated 96-well
plate with a density of 3000 cells/well. Cells were incubated with
different concentrations of doxorubicin (12.5 600nM, prepared in
culture medium) with(out) (200mM) monoHER. Dimethyl sulph-
oxide was used as a solubiliser for monoHER with a final
concentration of 0.1%, which did not show any antiproliferative
effect. Cells were washed (3 ) with warm medium 24h after
treatment and were left to grow for another 48h. Thereafter, the
MTT assay was performed according to Mosmann (1983) with
minor modifications. The percentage growth (proliferation) was
calculated by dividing the increase in the cell count (after the time
of the experiment, i.e. 3 days) of the treated cells by the increase of
the cell count of the untreated cells (which was taken as 100%
proliferation). The decrease in the proliferation capacity (as
percentage of control) was plotted as a function of the doxorubicin
concentration. The IC50 of doxorubicin with(out) monoHER was
estimated from the plot.
Cytotoxicity assay (LC50)
In the cytotoxicity studies confluent HUVECs were used. The LC50
was determined by treating confluent cells with different
concentrations of doxorubicin (0.5–25mM) with(out) monoHER
(0.2–1.2mM). The viability was measured 24h after treatment
using the MTT assay. Dimethyl sulphoxide, used as a solubilizer
for monoHER, reached a final concentration of 0.5%, which hardly
decreased (5%) the viability of confluent HUVECs. The percentage
viability (taking the control as 100% viability) was plotted as a
function of doxorubicin or monoHER concentration. The LC50 of
doxorubicin with(out) monoHER was estimated.
Isolation and preparation of calcein-labelled human
neutrophils
Isolation of neutrophils was performed as previously reported
(Schaefer et al, 1998) with a slight modification. In short, 24ml of
venous blood was drawn, by venipuncture, from healthy donors
into vacutainer tubes (Becton Dickinson, Plymouth, UK) contain-
ing 0.11 M sodium citrate and centrifuged at 1500g for 5min. The
buffy coat was carefully layered over a Ficoll solution and was
centrifuged at 540g for 20min at room temperature. Neutrophils
were isolated from the red pellet after the complete lysis of the
erythrocytes (with lysis buffer containing 0.15 M NH4Cl, 1mM
KHCO3 and 0.1 M Na2EDTA) at 01C followed by centrifugation at
380g for 5min at 41C. After counting, the cell density was adjusted
to 2.5 10
6 cell/ml in M199 medium. Neutrophils were labelled by
incubation with 2.5mM of the florescent indicator calcein AM in the
dark for 15min at 371C.
Neutrophil adhesion assay
Confluent HUVECs were incubated for 24h with different
concentrations (range 0.2–1.0mM) of doxorubicin, prepared in
M199 containing 10% human serum, alone or in combination with
1m M of monoHER (dissolved in 0.5% DMSO-containing medium).
Dimethyl sulphoxide did not affect the adhesion of neutrophils to
HUVECs in vitro. After stimulation, HUVECs were washed with
prewarmed M199 (2X). 100ml of the calcein-labelled neutrophils
was added per well and left to adhere for 1h at 371C. Subsequently,
the unbound neutrophils were thoroughly washed away with warm
PBS (3X). The fluorescent dye was released by lysis of the bound
neutrophils with 50ml of lysis buffer containing 1% NP40, 150mM
NaCl, 10mM Tris-HCl (pH 7.5), 5mM EDTA and 1mM PMSF. After
10min of shaking, the fluorescence was measured with a
spectrafluor multiplate reader TECAN (Salzburg, Austria) with
excitation and emission filters of 492 and 535nm, respectively. The
percentage adhesion (taking the control as zero percent adhesion)
was plotted as a function of doxorubicin concentration.
For the validation of the procedure, TNFa (1000Uml
 1) was
used as a positive control. As previously reported (Clark et al,
1997) TNFa stimulation caused an increase in neutrophil adhesion
of HUVECs with a factor of 2.5–4 compared to the blank.
Immunofluorescence microscopy
To localise neutrophil adhesion to doxorubicin-stimulated HU-
VECs, bound neutrophils were not lysed but fixed with 4%
paraformaldehyde for 15min. After washing, cells were incubated
with 10% FCS and 0.02 M glycine in PBS for 30min followed by
incubation with the primary antibodies CD 15 FITC (1:40
dilution) (Becton Dickinson, Leiden, The Netherlands) and
biotinylated ulex europaeus agglutinin 1 (1:100 dilution) (Vector
Laboratories, Inc., Burlingame, CA, USA) for the neutrophils and
the endothelial cells, respectively. After washing with PBS (3X),
streptavidin-Texas red (Vector Lab., Inc.), as fluorescent labelled
secondary antibody, was added (1:100 dilution) for the detection
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sof the biotinylated lectin. After washing, the wells were carefully
dried and mounted with Vectashield mounting medium for
fluorescence (H1200, Vector Lab. Inc.). Stained wells were
examined with an, LEICA confocal microscope showing neutro-
phils in green and HUVECs in red. A rarely appearing yellow
colour represented areas of coincident labelling with both
antibodies.
Expression of cell surface adhesion molecules
Confluent HUVECs, cultured in M199 containing 10% human
serum, were incubated for 24h with different concentrations
(range 0.08–1.0mM) of doxorubicin alone or in combination with
1m M of monoHER (dissolved in 0.13% DMSO-containing
medium). Dimethyl sulphoxide did not affect the expression of
the cell surface VCAM, ICAM or E-selectin. Under these
conditions, the positive control, that is, cells treated with TNFa
(10Uml
 1), induced between three- and five-fold increase in the
expression of all the adhesion molecules.
The expression of cell-bound VCAM-1, ICAM-1 and E-selectin
was measured as described earlier (Carlos et al, 1990). The colour
intensity was measured at a wavelength of 450nm. Experiments
were performed in triplicate. The results were expressed as
percentage of the control (taking the control as zero control),
which was plotted as a function of doxorubicin concentration.
Statistical analysis
The results are expressed as the mean value of three different days
(7s.e.m.). The value of each day represents the mean value of
three wells. The cells used on each day were obtained from a
separate umbilical cord. The overall effect of doxorubicin
with(out) monoHER was evaluated with ANOVA. When the
ANOVA indicated significant effect, the contrasts (differences) of
the effect of each concentration from the blank were investigated.
For monoHER protection, the contrast between monoHER effect at
each doxorubicin concentration (viz. the difference between
doxorubicinþmonoHER and doxorubicin alone) and monoHER
alone (viz. taking the change due to monoHER alone into account)
was also investigated.
The comparison of the IC50 or the LC50 of doxorubicin alone or
with monoHER was made using student’s t-test.
RESULTS
Antiproliferative effect of doxorubicin (IC50)
The antiproliferative effect of doxorubicin on HUVECs is shown in
Figure 1. Doxorubicin decreased the proliferation of endothelial
cells in a concentration-dependent manner and the IC50 was
60721nM after 24h. Coincubation with 200mM monoHER did not
significantly change the IC50 of doxorubicin (93754nM).
Cytotoxic effect of doxorubicin (LC50)
In this assay, confluent HUVECs were used to exclude proliferation
of the endothelial cells. Confluent HUVECs were 65-fold more
resistant to doxorubicin compared to proliferating cells and the
LC50 was 4.070.3mM.
The protective effect of different concentrations of monoHER
against 5mM doxorubicin (which is almost equal to the LC50 of
doxorubicin) is shown in Figure 2. Forty percent of HUVECs
remained viable after incubation with 5mM doxorubicin for 24h. 7-
Monohydroxyethlrutoside (0.2–1.2mM) alone did not affect the
viability of confluent HUVECs. Human vascular endothelial cells
were significantly protected against the cytotoxic effect of
doxorubicin at monoHER concentrations X0.8mM (P¼0.0014)
compared to doxorubicin alone. Maximum protection (about 30%
of the viability) was attained when a monoHER concentration of
X1m M (P¼0.0003) was used.
Figure 3 shows the viability of confluent HUVECs 24h after
exposure to different concentrations of doxorubicin with(out)
1m M monoHER. Doxorubicin significantly decreased the viability
of confluent HUVECs in a concentration-dependent manner
(Po0.00005). Coincubation with 1mM monoHER protected
endothelial cells against doxorubicin and the LC50 of doxorubicin
significantly increased from 470.3 to 40710mM (Po0.05). 7-
Monohydroxyethykrutoside protection was dependent on the
doxorubicin concentration: maximum protection was obtained
when the doxorubicin concentration was 5mM (Po0.00005) and
significant protection could still be obtained when doxorubicin
concentrations were p25mM (P¼0.0015).
Immunofluorescence microscopy
Immunofluorescence microscopy was used for the localization of
adhering neutrophils upon stimulation with doxorubicin with(out)
monoHER. As a result of the cellular damage induced by
doxorubicin, concentrations of p1mM were used in order to
reduce the nonspecific adhesion of neutrophils (i.e. to the
fibronectin-coated bottom). Figure 4 shows the adhesion of
neutrophils (in green) to HUVECs (in red) after stimulation with
0.6mM doxorubicin with(out) 1mM monoHER in comparison to
unstimulated cells (blank). Few neutrophils were bound to
unstimulated HUVECs. Neutrophil adhesion increased by stimula-
tion of HUVECs with 0.6mM doxorubicin. Neutrophils were
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Figure 1 The effect of doxorubicin with(out) monoHER on the
proliferation of HUVECs 24h after treatment compared to control. Values
are mean (n¼3)7s.e.m.
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Figure 2 The viability of endothelial cells 24h after treatment with 5mM
doxorubicin with(out) different concentrations of monoHER. Values are
mean (n¼3)þs.e.m. The P values, indicating monoHER concentrations
that significantly protected against the damaging effect of (5mM)
doxorubicin, were calculated with ANOVA.
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sspecifically bound to the endothelial cells as shown in Figure 4C
( 40). Coincubation with monoHER completely reverted doxor-
ubicin-induced neutrophil adhesion back to basal levels
(Figure 4D).
Adhesion of neutrophils to stimulated HUVECs
Figure 5 shows the percentage adhesion of neutrophils to confluent
HUVECs 24h after stimulation with different concentrations of
doxorubicin (0.2–1.0mM) alone or in combination with (1mM)
monoHER. Doxorubicin stimulation of endothelial cells resulted in
a significant increase in the percentage neutrophil adhesion, as
detected by the increase of the fluoresence, compared to the
control. This increase was concentration dependent and reached a
plateau at doxorubicin concentrations of X0.4mM (Po0.02). 7-
Monohydroxyethylrutoside alone did not affect the adhesion of
neutrophils to HUVECs. Simultaneous incubation with (1mM)
monoHER reverted doxorubicin-induced adhesion to the basal
levels (Figure 5).
Overexpression of cell bound adhesion molecules
Figures 6 and 7 show the expression of VCAM and E-selectin on
the surface of HUVECs, as a percentage from the control, 24h after
stimulation with different concentrations of doxorubicin with(out)
1m M monoHER. Both VCAM and E-selectin expression increased
significantly (Po0.002) after treatment with doxorubicin concen-
trations 40.6 and 40.8mM, respectively. The expression level of
ICAM did not change after the same treatment. The combined
treatment with 1mM monoHER reverted doxorubicin-stimulated
overexpression of VCAM and E-selectin to the basal levels.
DISCUSSION
7-Monohydroxyethylrutoside was recently used in the protection
against doxorubicin-induced cardiotoxicity in vivo (Van Acker
et al, 1997, 2000). The mechanism of protection is not fully
understood. The prevailing hypothesis is scavenging of free
radicals produced by doxorubicin and chelation of iron ions
(Haenen et al, 1993). Besides cardiotoxic properties, doxorubicin
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Figure 3 The viability of endothelial cells 24h after treatment with
different concentrations of doxorubicin with(out) 1mM monoHER. Values
are mean (n¼3)þs.e.m. The P values, which indicate the significant
protection of monoHER against the damaging effect of different
concentrations of doxorubicin, were calculated with ANOVA.
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Figure 4 Immunofluorescence microscopy of neutrophil (in green)
adhesion after stimulation with doxorubicin (0.6mM) with (out) 1mM
monoHER compared to unstimulated HUVECs (in red).
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Figure 5 The adhesion of neutrophils to HUVECs (expressed as
percentage of the control) was observed 24h after stimulation with
doxorubicin alone or in combination with (1mM) monoHER. Values are
mean (n¼3)7s.e.m. The P-values (*o0.02, **o0.01, ***o0.001), which
indicate significant protection of monoHER against doxorubicin-induced
neutrophil adhesion of HUVECs, were calculated with ANOVA.
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Figure 6 The overexpression of VCAM 24h after stimulation with
doxorubicin with(out) 1mM monoHER. Values are mean (n¼3)7s.e.m.
The P values (*o 0.002, **o 0.001), which indicate significant increase in
the expression of VCAM, were calculated with ANOVA.
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shas also inflammatory effects. It was therefore thought important
to study the role of monoHER against these inflammatory effects.
Thusfar the inflammatory effects of doxorubicin did not have
much attention. The inflammatory effects of doxorubicin were not
only found in the vasculature as phlebitis (Hecker, 1990) or as skin
inflammation after local treatment in the eye lid of several
laboratory animals (McLoon and Wirtschafter, 1997) but also in
the vicinity of the heart tissue. An increase in neutrophil adhesion
and thrombus formation has been found in the atrium of 75% of
mice repeatedly injected with 4mgkg
 1 doxorubicin (Fujihira et al,
1993). It is remarkable that the authors found associated damage
in the cardiomyocytes and the presence of interstitial inflamma-
tory cell infiltration. These findings suggest that the inflammatory
effect of doxorubicin may be directly or indirectly related to its
cardiotoxicity.
In the present study, we have illustrated the inflammatory effects
of doxorubicin in vitro. Doxorubicin reduced the viability of
resting endothelial cells with concentrations comparable to the
concentrations attained in the plasma of human and laboratory
animals (Mross et al, 1990; Van der Vijgh et al, 1990). In addition
to the direct damage to the vascular endothelial cells, doxorubicin
also induced neutrophil adhesion of vascular endothelial cells
in vitro.
In order to study the process of neutrophil adhesion to
doxorubicin-stimulated HUVECs, the expression of surface-bound
adhesion molecules was studied. The present study shows that
doxorubicin-induced neutrophil adhesion to stimulated HUVECs
was mediated via the overexpression of VCAM and E-selectin but
not via ICAM. Furthermore, it also shows that the overexpression
of VCAM occurs after stimulation with a lower concentration of
doxorubicin (0.6mM) than that for E-selectin (0.8mM doxorubicin).
Besides the inflammatory effect, the present study has also
illustrated that doxorubicin affects proliferating endothelial cells
much more markedly (IC50¼60nM) than resting (confluent) cells
(LC50¼4mM). Since proliferating endothelial cells are involved in
the neovascularisation (angiogenesis), this may indicate that a low
dose of doxorubicin may have an antiangiogenic effect without
affecting the vascular endothelium (resting endothelial cells with a
low turnover rate; Klohs and Hamby, 1999). This finding is
supported by Browder et al (2000), who have recently shown the
antiangiogenic effect of low-dose chemotherapy.
The present study is the first to show the anti-inflammatory
properties of the flavonoid monoHER. The addition of monoHER
significantly protected against doxorubicin damaging effect on
resting HUVECs in vitro. 7-Monohydroxyethylrutoside also
completely inhibited doxorubicin-induced neutrophil adhesion of
HUVECs in vitro. This protection may be mediated by the
observed inhibition of doxorubicin-induced VCAM and E-selectin
overexpression. On the other hand, monoHER did not protect
against the antiproliferative effect of doxorubicin.
The anti-inflammatory effect of the flavonoid monoHER could
be expected. Different flavonoids have an anti-inflammatory effect,
which plays a role in their therapeutic effect on allergy, asthma,
viral infection and gastric ulcers (Gerritsen et al, 1995; Havsteen,
1983). The good antioxidant and metal ion chelating properties of
monoHER (Haenen et al, 1993; Van Acker et al, 1993) play a role
in the protection of endothelial cells against the direct damage of
doxorubicin. These properties enable monoHER to protect against
doxorubicin-induced oxygen radicals, which induce lysis of the
endothelial cells and increase the vascular permeability and
reactivity (Clark et al, 1997). In addition, monoHER is one of
the constituents of Venoruton
s, which is used in the treatment of
chronic venous insufficiency by decreasing vascular permeability
and protecting vascular endothelial cells (Havsteen, 1983). The
protection of monoHER did not interfere with the antiproliferative
effect of doxorubicin. This is in line with our previous work where
monoHER protected against doxorubicin-induced cardiotoxicity
without interfering with its antiproliferative effect both in vitro and
in vivo (Van Acker et al, 1997).
The present in vitro study together with several publications,
pose an important question about a possible link between
doxorubicin-induced inflammatory effects and its cardiotoxicity.
Our in vitro data show that doxorubicin affected both the viability
and neutrophil adhesion of endothelial cells with clinically
achievable concentrations. Others have also shown that doxor-
ubicin has vascular effects in vivo. Doxorubicin was found to
disrupt the balance of several agents involved in the regulation of
vasodilatation, vasoconstriction and neutrophil adhesion in vivo,
for example, endothelin-1 (ET-1), histamine (Decorti et al, 1989,
1997; Duffy et al, 1999) and nitric oxide (NO) (Bristow et al, 1980),
leading to an imbalance in the physiology of the vasculature
especially after the long-term use of doxorubicin. Besides the
vascular imbalance, doxorubicin damage to endothelial cells could
cause endothelial dysfunction, which is known to induce
myocardial ischaemia, aggravate acute coronary syndromes and
accelerate progression of chronic artery disease (Britten and
Schachinger, 1998). These observations suggest the occurrence of
cardiovascular ailment after doxorubicin administration, which
pinpoints to a link between the inflammatory effects of doxor-
ubicin and its induced cardiotoxicity. As a result of the potential
clinical applicability, it is important to confirm the link between
the inflammatory effects of doxorubicin and its cardiotoxicity in
an in vivo model and to study the extent by which these
inflammatory effects participate in the development of the heart
disease. This can be studied by investigating whether the anti-
inflammatory effects of monoHER and other anti-inflammatory
agents could partially protect against doxorubicin-induced cardi-
otoxicity in vivo.
CONCLUSION
Doxorubicin, in clinically relevant concentrations, showed inflam-
matory effects in vitro (reduced the viability of HUVECs and
increased their propensity for neutrophil adhesion via VCAM and
E-selectin but not via ICAM). Proliferating endothelial cells were
much more sensitive to doxorubicin damage than resting
endothelial cells. 7-monohydroxyethylrutoside protected against
these inflammatory effects without interfering with the antiproli-
ferative effect of doxorubicin. The possibility of a relation between
doxorubicin-induced-inflammatory effects and its cardiotoxicity
should be further investigated in vivo.
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Figure 7 The overexpression of E-selectin 24h after stimulation with
doxorubicin with(out) 1mM monoHER. Values are mean (n¼3)7s.e.m.
The P values (*o 0.001, **o 0.0005), which indicate significant increase in
the expression of VCAM, were calculated with ANOVA.
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